翰宇药业涨2.09%，成交额9499.71万元，主力资金净流入518.97万元

Group 1 - The core viewpoint of the news is that Hanyu Pharmaceutical has shown significant stock price fluctuations and strong financial performance in recent months, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of November 24, Hanyu Pharmaceutical's stock price increased by 2.09% to 18.11 CNY per share, with a total market capitalization of 15.996 billion CNY [1] - The company has experienced a 40.50% increase in stock price year-to-date, but has seen a decline of 6.65% in the last five trading days and 16.89% over the last 20 days [1] - For the period from January to September 2025, Hanyu Pharmaceutical achieved a revenue of 683 million CNY, representing a year-on-year growth of 82.06%, and a net profit of 71.35 million CNY, which is a 305.00% increase compared to the previous year [2] Group 3 - Hanyu Pharmaceutical has not distributed any dividends in the last three years, with a total payout of 417 million CNY since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased to 110,100, with an average of 6,771 circulating shares per person, a decrease of 42.81% from the previous period [2][3] - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 33.5479 million shares, an increase of 25.8662 million shares from the previous period [3]